CSG tops earnings and revenue estimates, confirms outlook; shares slide By Investing.com

CSG reported FY2025 revenue €6.74bn, up 72% (organic +30%) and ~5% above consensus/company guidance (€6.4bn); adjusted EBIT €1.63bn (+31% organic) with a 24.1% EBIT margin (lower end of 24–25% guidance). Net profit rose to €694.1m (+~35% YoY), pretax €1.18bn (vs €853.4m in 2024), and pre-tax free cash flow was €61m; order backlog stands at €15bn. The group reaffirmed 2026 revenue guidance of €7.4–7.6bn and cited demand tailwinds from elevated defense spending plus the integration of Kinetic Group; shares fell ~5.6% intraday.

Analysis

The print reinforces a structural story: ammunition and munitions exposure converts geopolitical risk into multi-year earnings visibility, but that visibility shifts the battle from demand uncertainty to supply-side execution and cash conversion. Expect a capex and subcontractor cycle to reaccelerate as management converts backlog into output; this will lift machine-tool, automation and specialty-chemicals SMEs first (6–24 months) and compress margins transiently as capacity scales.

Integration of a U.S. ammo platform materially changes currency, contract and working-capital dynamics — USD-denominated revenues reduce sales volatility but increase FX mismatch on EUR-denominated costs and pension liabilities; hedging cadence and contract indexation will be a principal driver of reported margins over the next 4–12 quarters.

Second-order winners include niche vendors of case-head etching, propellant production and automated cartridge-loading equipment — these businesses can reprice and tighten delivery windows, creating pricing power even if prime margins normalize. Conversely, mid-tier European suppliers with single-line exposure and high leverage are at elevated risk of being squeezed or acquired in a consolidation wave (12–36 months), creating asymmetric outcomes across the supplier base.

Key tail risks: (1) rapid geopolitical de-escalation that rerates order probabilities within 3–9 months; (2) export-control or M&A regulatory friction in transatlantic deals that delays synergies beyond 12–18 months; (3) sustained weak free-cash conversion if working capital normalization lags, forcing equity dilution or delayed buybacks.

Key Decisions for Investors

• Long AS:CSG (Amsterdam: CSG) — accumulator entry on intraday weakness sized 2–3% NAV, horizon 6–12 months. Rationale: capture re-rating from visible order conversion and operational leverage; target +25–35% upside if FCF normalizes and margins tick up, stop at -15% to limit execution/FCF risk.
• Pair trade — Long AS:CSG / Short RHM.DE (Rheinmetall) 1:0.6 by notional, horizon 3–9 months. Rationale: relative exposure to pure-play ammunition scarcity vs diversified prime execution risk; expected to outperform if backlog conversion is clean. Risk: defense sector-wide rerate would hurt both — cut if spread narrows >10% vs entry.
• Buy AS:CSG call spread (12–18 month expiry) to limit premium outlay — buy near-ATM call, sell 25–30% OTM call. Position size 1–2% NAV. Rationale: convex payoff to capture integration re-rating and margin expansion while capping downside to premium paid.